Matthew Sherman
Chief Tech/Sci/R&D Officer bei DECIPHERA PHARMACEUTICALS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Matthew L.
Sherman currently works at Pulmatrix Operating Co., Inc., as Director, Pieris Pharmaceuticals, Inc., as Independent Director from 2018, Deciphera Pharmaceuticals, Inc., as Chief Medical Officer & Executive Vice President from 2019, and Geisel School of Medicine, as Member-Alumni Council.
Dr. Sherman also formerly worked at NewLink Genetics Corp., as Director from 2018 to 2020, Wyeth Pharmaceuticals LLC, as Area Director-Therapeutic Oncology in 2013, Pulmatrix, Inc., as Independent Director from 2016 to 2020, Genetics Institute LLC, as Head-Clinical Research & Development in 2013, Acceleron Pharma, Inc., as Chief Medical Officer & Executive Vice President from 2015 to 2018, Synta Pharmaceuticals Corp., as Chief Medical Officer & Senior Vice President from 2004 to 2006, Dana-Farber Cancer Institute, Inc., as Assistant Clinical Professor, The Brigham & Women's Hospital, Inc., as Professor, The Marine Biological Laboratory, as Member, and Harvard Medical School, as Assistant Clinical Professor in 2001.
Dr. Sherman received his undergraduate degree from Massachusetts Institute of Technology and doctorate degree from Dartmouth Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 16.02.2024 | 108 739 ( 0,13% ) | 2 Mio $ | 31.03.2024 | |
| 21.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Matthew Sherman
| Unternehmen | Position | Beginn |
|---|---|---|
| PIERIS PHARMACEUTICALS, INC. | Director/Board Member | 25.10.2018 |
| DECIPHERA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 02.10.2019 |
Pulmatrix Operating Co., Inc.
 Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Director/Board Member | - |
| Geisel School of Medicine | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Matthew Sherman
| Unternehmen | Position | Ende |
|---|---|---|
| LUMOS PHARMA, INC. | Director/Board Member | 18.03.2020 |
| PULMATRIX, INC. | Director/Board Member | 31.01.2020 |
| ACCELERON PHARMA INC. | Chief Tech/Sci/R&D Officer | 05.07.2018 |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Chief Tech/Sci/R&D Officer | 01.01.2006 |
| Harvard Medical School | Corporate Officer/Principal | 01.01.2001 |
Ausbildung von Matthew Sherman
| Massachusetts Institute of Technology | Undergraduate Degree |
| Dartmouth Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| PIERIS PHARMACEUTICALS, INC. | Health Technology |
| PULMATRIX, INC. | Health Technology |
| DECIPHERA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 9 |
|---|---|
Genetics Institute LLC
 Genetics Institute LLC Pharmaceuticals: MajorHealth Technology Genetics Institute LLC develops pharmaceutical products through recombinant DNA and other genetic technologies. It develops drugs to make the blood of hemophiliacs clot, as well as substances that stimulate the production of red and white blood cells and proteins that enhance bone growth. The company was founded in 1980 and is headquartered in Cambridge, MA. | Health Technology |
NewLink Genetics Corp.
 NewLink Genetics Corp. Pharmaceuticals: MajorHealth Technology NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. It products include HyperAcute Pancreas, HyperAcute Lung, HyperAcute Melanoma, HyperAcute Imunotherapies, NLG8189, and IDO Pathway Inhibitors. The company was founded by Charles J. Link and Nicholas N. Vahanian on June 4, 1999 and is headquartered in Ames, IA. | Health Technology |
Pulmatrix Operating Co., Inc.
Pulmatrix Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Pulmatrix Operating Co., Inc. develops pharmaceutical products for respiratory infectious diseases. Its iSPERSE powders can be used with an array of dry powder inhaler technologies and can be formulated with virtually any drug substance. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer in 2003 and is headquartered in Lexington, MA. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
Wyeth Pharmaceuticals LLC
 Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA. | Health Services |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
The Marine Biological Laboratory
 The Marine Biological Laboratory Miscellaneous Commercial ServicesCommercial Services The Marine Biological Laboratory provides research and educational services. It offers a range of courses, workshops, conferences, and internships, discovery-based education programs and courses. The firm s a private marine laboratory, supporting scientists and staff working in such fields as cell and developmental biology, ecology, microbiology, molecular evolution, global infectious disease, neurobiology, and sensory physiology. The company was founded in 1888 and is headquartered in Woods Hole, MA. | Commercial Services |
